Breaking News
Investing Pro 0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free
Close

Merck & Company Inc (MRK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Merck&Co's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
86.18 -0.60    -0.69%
15:59:59 - Closed. Currency in USD ( Disclaimer )
After Hours
85.96
-0.22
-0.26%
19:58:55 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 8,778,159
  • Bid/Ask: 85.35 / 87.00
  • Day's Range: 85.29 - 86.71
Merck&Co 86.18 -0.60 -0.69%

MRK Income Statement

 
Featured here, the Income Statement (earnings report) for Merck & Company Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).
AnnualQuarterly
InvestingPro Advanced Income Statement
Period Ending: 2022
30/06
2022
31/03
2021
31/12
2021
30/09
Total Revenue 14593 15901 13521 13154
Revenue 14593 15901 13521 13154
Other Revenue, Total - - - -
Cost of Revenue, Total - 5334 3827 3402
Gross Profit - 10567 9694 9752
Total Operating Expenses - 10332 9946 8338
Selling/General/Admin. Expenses, Total - 2302 2820 2331
Research & Development - 2569 3061 2437
Depreciation / Amortization - - - -
Interest Expense (Income) - Net Operating - - - -
Unusual Expense (Income) - 127 238 168
Other Operating Expenses, Total - - - -
Operating Income - 5569 3575 4816
Interest Income (Expense), Net Non-Operating - -983 110 448
Gain (Loss) on Sale of Assets - - - -
Other, Net - 275 224 2
Net Income Before Taxes 4487 4861 3909 5266
Provision for Income Taxes 538 554 85 695
Net Income After Taxes 3949 4307 3824 4571
Minority Interest - 3 -4 -4
Equity In Affiliates - - - -
U.S GAAP Adjustment - - - -
Net Income Before Extraordinary Items 3944 4310 3820 4567
Total Extraordinary Items - - -62 -
Net Income 3944 4310 3758 4567
Total Adjustments to Net Income - 6 - -
Income Available to Common Excluding Extraordinary Items 3944 4310 3820 4567
Dilution Adjustment 7 - - -
Diluted Net Income 3937 4310 3758 4567
Diluted Weighted Average Shares 2540 2537 2535 2536
Diluted EPS Excluding Extraordinary Items 1.55 1.7 1.51 1.8
DPS - Common Stock Primary Issue 0.69 0.69 0.69 0.65
Diluted Normalized EPS - 1.52 2 2.01
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the income statement, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

MRK Comments

Write your thoughts about Merck & Company Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
William Hineser
William Hineser Aug 25, 2022 10:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good write up in WSJ today. Should be up.
Rob Roo
Rob Roo Jul 20, 2022 6:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀🚀🚀🚀🚀🚀🚀
Christopher Zingone
Christopher Zingone May 20, 2022 12:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This will be 120+ soon
NY Brokers Stock Exchange
NY Brokers Stock Exchange May 20, 2022 12:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why Mr. Zingone at 120+ soon ? any reason please ? if you can help me i will appreciate so much . Best Regards, Elon.
Sylvia Doloff
Sylvia Doloff May 20, 2022 12:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
you are in outer space
Sylvia Doloff
Sylvia Doloff May 20, 2022 12:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
help you need to figure it out on your own listening to mrons and thier baseless predictions how is that working for you
Christopher Zingone
Christopher Zingone May 20, 2022 12:49PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NY Brokers Stock Exchange As soon as they start selling their covid drug in USA
black cat
black cat May 16, 2022 12:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ma e' sui massimi da sempre? che t.p. si puo' immaginare a questo punto ?
Rob Roo
Rob Roo Apr 28, 2022 1:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
🚀🚀🚀🚀🚀🚀🚀🌜
Taras Khomitsky
Taras Khomitsky Apr 28, 2022 8:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Good, even great reasults in first quater of 2022.Let's hope to go back to 86-87 territory
Fever Factory
Fever Factory Apr 20, 2022 5:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention.
Fever Factory
Fever Factory Apr 20, 2022 5:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
Fever Factory
Fever Factory Apr 20, 2022 5:55PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
William Hineser
William Hineser Apr 02, 2022 9:07AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It was 22 in 1995. Do the math and look at the products.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email